{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T18:13:45Z","timestamp":1772820825753,"version":"3.50.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T00:00:00Z","timestamp":1771027200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T00:00:00Z","timestamp":1771027200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s40120-026-00888-1","type":"journal-article","created":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T16:32:46Z","timestamp":1771086766000},"page":"775-791","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Time and Motion Study to Quantify Time for Tysabri (Natalizumab) Intravenous Versus Subcutaneous to Treat Relapsing-Remitting Multiple Sclerosis in France, Spain, and the United Kingdom"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1623-9169","authenticated-orcid":false,"given":"Erwin","family":"De Cock","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khalil","family":"Jomaa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jyothi","family":"Menon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Acosta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rona","family":"Esquejo-Leon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Oliver-Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,14]]},"reference":[{"issue":"9","key":"888_CR1","first-page":"2823","volume":"25","author":"JJ Body","year":"2017","unstructured":"Body JJ, Gatta F, De Cock E, Tao S, Kritikou P, Wimberger P, et al. An observational time and motion study of denosumab subcutaneous injection and zoledronic acid intravenous infusion in patients with metastatic bone disease: results from three European countries. Support Care Cancer. 2017;25(9):2823\u201332.","journal-title":"Support Care Cancer"},{"issue":"6","key":"888_CR2","doi-asserted-by":"publisher","first-page":"e0157957","DOI":"10.1371\/journal.pone.0157957","volume":"11","author":"E De Cock","year":"2016","unstructured":"De Cock E, Kritikou P, Sandoval M, Tao S, Wiesner C, Carella AM, et al. Time savings with rituximab subcutaneous injection versus rituximab intravenous infusion: a time and motion study in eight countries. PLoS ONE. 2016;11(6):e0157957.","journal-title":"PLoS ONE"},{"issue":"3","key":"888_CR3","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1002\/cam4.573","volume":"5","author":"E De Cock","year":"2016","unstructured":"De Cock E, Pivot X, Hauser N, Verma S, Kritikou P, Millar D, et al. A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2-positive early breast cancer. Cancer Med. 2016;5(3):389\u201397.","journal-title":"Cancer Med"},{"key":"888_CR4","unstructured":"European Medicines Agency (EMA). Tysabri: EPAR\u2014product information. Extension of marketing authorisation to include subcutaneous administration. EMA\/135241\/2021. 2021. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/tysabri. Accessed 24 Oct 2025."},{"issue":"1","key":"888_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-018-0041-4","volume":"4","author":"M Filippi","year":"2018","unstructured":"Filippi M, Bar-Or A, Piehl F, Preziosa P, Solari A, Vukusic S, et al. Multiple sclerosis. Nat Rev Dis Primers. 2018;4(1):43. https:\/\/doi.org\/10.1038\/s41572-018-0041-4.","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"888_CR6","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1007\/s00415-023-11955-0","volume":"271","author":"M Filippi","year":"2024","unstructured":"Filippi M, Grimaldi L, Conte A, Totaro R, Valente MR, Malucchi S, et al. Intravenous or subcutaneous natalizumab in patients with relapsing-remitting multiple sclerosis: investigation on efficiency and savings\u2014the EASIER study. J Neurol. 2024;271(1):340\u201354.","journal-title":"J Neurol"},{"issue":"17","key":"888_CR7","doi-asserted-by":"publisher","first-page":"175628642412413","DOI":"10.1177\/17562864241241382","volume":"13","author":"R Gold","year":"2024","unstructured":"Gold R, Schmidt S, Deisenhammer F, Motte J, Richter N, Taipale K, et al. Real-world evidence and patient preference for subcutaneous versus intravenous natalizumab in the treatment of relapsing-remitting multiple sclerosis\u2014initial results from the observational SISTER study. Ther Adv Neurol Disord. 2024;13(17):17562864241241382.","journal-title":"Ther Adv Neurol Disord"},{"key":"888_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-059288","volume":"13","author":"HW Lin","year":"2023","unstructured":"Lin HW, Lin CY, Yeh TP, et al. Quality of care in the course of subcutaneous versus intravenous mixed-methods research. BMJ Open. 2023;13:e059288.","journal-title":"BMJ Open"},{"key":"888_CR9","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.jbi.2014.02.017","volume":"49","author":"M Lopetegui","year":"2014","unstructured":"Lopetegui M, Yen PY, Lai A, et al. Time motion studies in healthcare: what are we talking about? J Biomed Inform. 2014;49:292\u20139.","journal-title":"J Biomed Inform"},{"key":"888_CR10","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1016\/S1470-2045(13)70383-8","volume":"14","author":"X Pivot","year":"2013","unstructured":"Pivot X, Gligorov J, M\u00fcller V, Barrett-Lee P, Verma S, Knoop A, et al. Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study. Lancet Oncol. 2013;14:962\u201370.","journal-title":"Lancet Oncol"},{"issue":"10","key":"888_CR11","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1002\/jcph.707","volume":"56","author":"T Plavina","year":"2016","unstructured":"Plavina T, Fox EJ, Lucas N, Muralidharan KK, Mikol D. A randomized trial evaluating various administration routes of natalizumab in multiple sclerosis. J Clin Pharmacol. 2016;56(10):1254\u201362.","journal-title":"J Clin Pharmacol"},{"issue":"9","key":"888_CR12","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/NEJMoa044397","volume":"354","author":"CH Polman","year":"2006","unstructured":"Polman CH, O\u2019Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899\u2013910.","journal-title":"N Engl J Med"},{"key":"888_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.105380","volume":"82","author":"D Rog","year":"2024","unstructured":"Rog D, Brownlee W, Carod-Artal FJ, Kalra S, Barker N, Lowndes C, et al. Quantifying the administration and monitoring time burden of several disease-modifying therapies for relapsing multiple sclerosis in the United Kingdom: a time and motion study. Multiple Scler Relat Disord. 2024;82:105380.","journal-title":"Multiple Scler Relat Disord"},{"key":"888_CR14","first-page":"Poster 467","volume":"99","author":"M Rummel","year":"2014","unstructured":"Rummel M, Kim TM, Plenteda C, Capochiani E, Mendoza M, Smith R, et al. Patient preference for subcutaneous or intravenous administration of rituximab in previously untreated CD20+ non-Hodgkin lymphoma: interim data from the PrefMab study. Haematologica (EHA Annual Congress Abstracts). 2014;99:Poster 467.","journal-title":"Haematologica (EHA Annual Congress Abstracts)"},{"issue":"3","key":"888_CR15","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s41669-023-00394-2","volume":"7","author":"AM Torres","year":"2023","unstructured":"Torres AM, Ar\u00e9valo Bernab\u00e9 AG, Becerril R\u00edos N, Hell\u00edn Gil MF, Mart\u00ednez Sesmero JM, Meca Lallana V, et al. Cost-analysis of subcutaneous vs intravenous administration of natalizumab based on patient care pathway in multiple sclerosis in Spain. Pharmacoecon Open. 2023;7(3):431\u201341.","journal-title":"Pharmacoecon Open"},{"issue":"14","key":"888_CR16","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1177\/13524585211003020","volume":"27","author":"M Trojano","year":"2021","unstructured":"Trojano M, Rami\u00f3-Torrent\u00e0 L, Grimaldi LM, Lubetzki C, Schippling S, Evans KC, et al. A randomized study of natalizumab dosing regimens for relapsing-remitting multiple sclerosis. Multiple Scler. 2021;27(14):2240\u201353.","journal-title":"Multiple Scler"},{"key":"888_CR17","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1200\/OP.24.00021","volume":"21","author":"AG Waks","year":"2025","unstructured":"Waks AG, Chen EL, Graham N, et al. Subcutaneous vs intravenous trastuzumab\/pertuzumab: a time and motion substudy of a phase II trial of adjuvant trastuzumab\/pertuzumab for stage I HER2+ breast cancer (ADEPT trial). JCO Oncol Pract. 2025;21:351\u20137.","journal-title":"JCO Oncol Pract"},{"issue":"14","key":"888_CR18","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1177\/1352458520970841","volume":"26","author":"C Walton","year":"2020","unstructured":"Walton C, King R, Rechtman L, Kaye W, Leray E, Marrie RA, et al. Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS, third edition. Multiple Scler. 2020;26(14):1816\u201321.","journal-title":"Multiple Scler"},{"key":"888_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2019.101861","volume":"38","author":"T Ziemssen","year":"2020","unstructured":"Ziemssen T, Tolley C, Bennett B, Kilgariff S, Jones E, Pike J, et al. A mixed methods approach towards understanding key disease characteristics associated with the progression from RRMS to SPMS: physicians\u2019 and patients\u2019 views. Multiple Scler Relat Disord. 2020;38:101861.","journal-title":"Multiple Scler Relat Disord"},{"issue":"6","key":"888_CR20","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.smim.2009.08.003","volume":"21","author":"RL Zuvich","year":"2009","unstructured":"Zuvich RL, McCauley JL, Pericak-Vance MA, Haines JL. Genetics and pathogenesis of multiple sclerosis. Semin Immunol. 2009;21(6):328\u201333.","journal-title":"Semin Immunol"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00888-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-026-00888-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00888-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T12:08:03Z","timestamp":1772798883000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-026-00888-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,14]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["888"],"URL":"https:\/\/doi.org\/10.1007\/s40120-026-00888-1","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,14]]},"assertion":[{"value":"1 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Erwin De Cock and Jyothi Menon were employees of Syneos Health at the time of the study; they are no longer affiliated. Peter Oliver-Smith, Carlos Acosta, and Rona Esquejo-Leon are current employees of Biogen and may hold stock\/options. Khalil Jomaa is a former Biogen employee and may hold stock\/options.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Regulatory classification and ethics approvals varied by country. In France, the study was classified as\n                      Recherche Non Impliquant la Personne Humaine\n                      (RNIPH [Research Not Involving Human Subjects]), declared to the Commission Nationale de l\u2019Informatique et des Libert\u00e9s (CNIL) and registered to the Health Data Hub on 8 December 2022 (registration no. F20221208091708). In Spain, the Instituto de Investigaci\u00f3n Biom\u00e9dica de Girona Josep Trueta (IDIBGI) determined that the study did not meet the definition of a prospective observational drug study and that no ethics submission was required. In the UK, the study was classified as a non-Clinical Trial of an Investigational Medicinal Product (non-CTIMP) and received a favorable opinion from the London-Brent Research Ethics Committee, with approval from the Health Research Authority and Health and Care Research Wales (IRAS Project ID: 318021; REC reference: 23\/PR\/0266). The T&M study was conducted in compliance with the approved protocol, the applicable principles outlined in Good Pharmacoepidemiology Practice guidelines, and the Declaration of Helsinki (1964 and its later amendments). Any adverse events associated with natalizumab were to be reported via normal reporting processes for a marketed product in compliance with applicable regulatory requirements. As for any observational study, the decision to treat a patient with natalizumab IV or SC was taken as part of routine care and was independent of this study. No patient personally identifiable information was collected; hence, no informed consent was required from patients. However, patients were informed via an Information Leaflet of the study and its purpose and asked for their verbal agreement (or refusal) for their natalizumab administration process to be observed.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}